Ruchi Sharma, APRN
Adult Health · Farmington, CTNPI 1902240039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 209 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$651
- Novo Nordisk$624
- Lilly USA, LLC$500
- Pfizer$339
- Boehringer Ingelheim$277
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$276
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,602100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $651 |
| Novo Nordisk | 29 | $624 |
| Lilly USA, LLC | 23 | $500 |
| Pfizer | 12 | $339 |
| Boehringer Ingelheim | 11 | $277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $276 |
| Abbott | 14 | $272 |
| AstraZeneca | 10 | $215 |
| Amgen(2 entities) | 11 | $197 |
| Exact Sciences | 8 | $196 |
| GSK | 7 | $161 |
| Astellas Pharma US Inc | 4 | $115 |
| Johnson & Johnson | 4 | $84 |
| Amarin Pharma, Inc. | 4 | $79 |
| Arbor Pharmaceuticals, Inc. | 4 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Genentech USA, Inc. | 2 | $34 |
| Agios Pharmaceuticals, Inc. | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Eisai Inc. | 1 | $27 |
| Ardelyx, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Merck | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELISTOR$143
How this compares
$4,602 in reported general payments places this provider in the 85th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 17 | $39,268 |
| JanuviaSitagliptin Phosphate | 22 | $36,717 |
| JardianceEmpagliflozin | 12 | $17,285 |
| EliquisApixaban | 12 | $12,632 |
| Atorvastatin Calcium | 173 | $1,404 |
| Colesevelam Hcl | 18 | $1,268 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,142 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $946 |
| Omeprazole | 32 | $822 |
| Levothyroxine Sodium | 65 | $691 |
| Pantoprazole Sodium | 64 | $572 |
| Amlodipine Besylate | 105 | $536 |
| Azelastine Hcl | 25 | $506 |
| Lisinopril | 75 | $483 |
| Sertraline Hcl | 39 | $408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $500 | $39,26817 claims |
| MerckJanuvia | $19 | $36,71722 claims |
| Boehringer IngelheimJardiance | $277 | $17,28512 claims |
| PfizerEliquis | $339 | $12,63212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $69165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 418 adult health providers in Connecticut.
Other adult health in Farmington
- Genice NelsonFarmington$36K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.